Background: Red cell distribution width (RDW) is a novel prognostic marker independently associated with adverse outcomes in acute decompensated heart failure (ADHF) patients. The aim of the present study was to assess whether the change in RDW after discharge had prognostic value in patients with ADHF.
he risk stratification of patients admitted with acute decompensated heart failure (ADHF) is determined by measuring prognostically significant biomarkers. Red cell distribution width (RDW) is a measurement of size variability of the red blood cells, easily measured using modern cell counters. Generally, a high RDW may reflect reticulocytosis due to iron deficiency anemia and hemolytic disorders. Recently, RDW has been found to be a novel prognostic marker in patients with heart failure (HF), 1-6 prior myocardial infarction without HF, 7,8 and pulmonary hypertension. 9 Two large epidemiologic studies further suggested that RDW was associated with all-cause mortality including cardiovascular (CV) mortality even in a cohort without anemia, or iron, folate and vitamin B deficiency. 10, 11 ADHF is the most common cause for hospitalization for patients >65 years of age. 12 Therefore, accurate prediction of ADHF outcome is needed and many approaches for this have been suggested. To date, B-type natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP), cardiac troponins, C-reactive protein, uric acid, soluble interleukin-1 receptor family member ST2 (ST2) and their combinations have been found to be related to the severity and prognosis of patients with ADHF. 13, 14 Serial monitoring and interval change as well as initial value have also been found to be well associated with prognosis in CV disease patients including HF. [15] [16] [17] [18] Recent studies have reported that both RDW levels at admission and at discharge are prognostic markers independent of NT-proBNP in ADHF patients. 2,3, 5 No study, however, has investigated repeated measurements of RDW and its prognostic value in ADHF patients. We investigated the prognostic value of change in RDW via measurements at admission, at discharge, and 1 month after discharge in patients with ADHF. was used to test the influence of the change in RDW on CV events, with log-rank test. The independent effect of variables on CV events was calculated using Cox multivariate proportional hazards regression analysis, incorporating covariates with P<0.10 on univariate analysis. Hazard ratio (HR) with 95% confidence interval (CI) demonstrated the risk of CV events. P<0.05 was considered significant and all reported probability values were 2-tailed.
Results

Baseline Characteristics of ADHF Patients and Clinical Outcomes
The baseline characteristics are summarized in Table 1 . The etiology of HF was idiopathic dilated cardiomyopathy in 77 patients (29.5%), valvular in 45 (17.2%), ischemic in 87 (33.3%) and hypertensive in 17 (6.5%). No significant differences were observed in dobutamine infusion therapy at admission and discharge medications between patients without CV events and with CV events. As compared with patients without CV events, patients who developed CV events had significantly higher previous admission history, lower ischemic origin, lower systolic blood pressure (SBP), lower eGFR, lower Hbadm, lower Hbdis, lower Hb1Mdis, higher RDWadm, higher RDWdis, and higher RDW1Mdis. During a median follow-up of 636 days (IQR, 228-912 days), CV events occurred in 54.0% of patients (141/261), and CV mortality in 12.6% (33/261). The incidence of positive RDW∆1Mdis-adm was significantly higher in patients who developed CV events than patients without CV events (P=0.023). Moreover, LVEF, NTproBNP and discharge medications were not significantly different between the two groups.
Changes in RDW After ADHF Mean RDW changed from 14.2±2.0% at admission to 14.3±1.7% at discharge (P=0.493) to 14.4±1.9% at 1 month after discharge (P=0.028). Mean RDW∆dis-adm was 0.06±1.26% and RDW∆1Mdis-adm was 0.12±1.39%. The distribution of RDW∆dis-adm and RDW∆1Mdis-adm are shown in Figure 1 . In correlation analysis, RDW∆1Mdis-adm was significantly correlated with RDW∆dis-adm (r=0.787, P<0.001), Hb∆dis-adm (r=-0.246, P<0.001) and Hb∆1Mdis-adm (r=-0.246, P<0.001) but not with BUN∆1Mdis-adm (r=-0.049, P=0.434) nor with creatinine∆1Mdis-adm (r=0.041, P=0.516).
RDW∆1Mdis-adm as an Independent Predictor of CV Events
The primary composite endpoint of the present study was CV events including CV mortality and rehospitalization for HF. On Kaplan-Meier survival analysis, the positive RDW∆dis-adm group (n=109) tended to have a higher number of CV events compared with the no-positive RDW∆dis-adm group (n=152), but this was not significant (57.6% vs. 49.6%, log-rank P=0.115; Figure 2A ). The positive RDW∆1Mdis-adm group (n=136) had a significantly higher number of CV events compared with the no-positive RDW∆1Mdis-adm group (n=125; 60.3% vs. 47.2%; log-rank P=0.007; Figure 2B) Table 3) .
Addition of RDW∆1Mdis-adm to RDWadm Increases Prognostic Value
We tested whether the addition of RDW∆1Mdis-adm has an incremental effect on prognostic value when added to RDWadm by dividing patients into 2 groups according to RDWadm. On Kaplan-Meier survival analysis, a group with both high RDWadm (≥13.8%) and positive RDW∆1Mdis-adm (n=51) had a significantly higher number of CV events than a group with high RDWadm and no-positive RDW∆1Mdis-adm (n=75), a group with low RDWadm (<13.8%) and positive RDW∆1Mdis-adm (n=85) and a group with low RDWadm and no-positive RDW∆1Mdis-adm (n=50) (72.5% vs. 52.9% vs. 56.0% vs. 34.0%; log-rank P<0.001; Figure 3) . In a Cox proportional hazards model, the addition of positive RDW∆1Mdis-adm to RDWadm significantly increased the likelihood of prediction of CV events (global chi-square 36.2 vs. 43.9, P=0.007; Figure 4 ).
Discussion
The principal findings of the present study are that positive RDW∆1Mdis-adm is an independent prognostic factor for CV events in ADHF patients, and that repeated measurements of RDW have an increased prognostic value for predicting CV events to single measurement of RDW in these patients. Herein we report interesting data on the potential relationship between positive RDW∆1Mdis-adm and CV events after ADHF.
Repeated Measurements of RDW After ADHF
RDW was first found to be a prognostic marker in symptomatic chronic HF patients in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) study. 1 Further studies showed that higher RDW levels at admission and at discharge were associated with poor long-term outcomes regardless of anemia status, thereby demonstrating increased prognostic power compared to NTproBNP in patients with ADHF. 2-5 Repeated measurements and the change in biomarker over time are known to have additive prognostic value compared to single measurements, because the hemodynamic status changes over time after ADHF. The prognostic value of serial measurements of BNP, NT-proBNP and ST2 has been investigated in patients with HF. 18,20-23 Recently, Dabbah et al reported that an increase in RDW during hospital stay was associated with poor clinical outcomes, and demonstrated the prognostic importance of serial measurements of RDW in patients with acute myocardial infarction. 8 In the present study we observed that positive RDW∆1Mdis-adm could significantly predict adverse CV events, but positive RDW∆dis-adm could not, although there was a significant correlation between RDW∆1Mdis-adm and RDW∆dis-adm. Also, we did not find a significant difference in CV events according to absolute change of RDW∆1Mdis-adm (data not shown). This discrepancy could be explained by the relatively small size of the present subject cohort. Thus, we expect that significant predictive power of positive RDW∆dis-adm could be demonstrated in a large-scale study in the future. The present results show that CV mortality was not different between the positive RDW∆1Mdis-adm and the no-positive RDW∆1Mdis-adm groups. This might be because we did not include in-hospital mortality in the present study. One of the main CV events is in-hospital death in patients with ADHF. In addition to RDW∆1Mdis-adm, RDWadm was also an independent predictor for CV events in the multiple Cox regression model, which is compatible with previous studies. 2,3,5 Moreover, the high RDWadm and the positive RDW∆1Mdis-adm groups had a significantly higher number of CV events than the other groups. Therefore, positive RDW∆1Mdis-adm has an increased prognostic value compared to RDWadm for the prediction of CV events in ADHF patients.
RDW as a Surrogate Marker of Multiple Pathophysiologies in HF
It is unclear whether RDW has a pathophysiological role in HF or whether it simply identifies a population with severe LV dysfunction. Several mechanisms, however, have been suggested to explain the increase in RDW and how it works as a prognostic marker in patients with ADHF. First, persistent inflammation is known to be a principal pathophysiologic finding and poor prognostic factor for HF. 24 Several studies have shown that increased RDW levels in patients with ADHF are associated with increased inflammatory status. 6,25,26 Second, an increase in RDW is associated with increased oxidative stress that characterizes exacerbation of heart failure. 27, 28 Because oxidative stress is related to red cell survival, it could explain the increase in RDW in ADHF patients. 29 Third, increased RDW may be associated with increased hemodynamic overload, which is important in the mechanism of HF exacerbation. Our previous study demonstrated that high RDW levels were significantly associated with elevated early mitral inflow velocity to early diastolic mitral annular velocity (E/E') after adjusting NT-proBNP. 19 Furthermore, a high RDW was correlated with higher erythropoietin, lower serum iron and total iron binding capacity saturation in patients with chronic HF. 26 This means that the ability to mobilize and use iron stores may be impaired. Finally, a recent report showed that increased RDW was associated with troponin T, a marker of myocardial injury. 30 All these suggested mechanisms may explain why RDW is an independent predictive and prognostic marker in patients with ADHF, indicating that RDW may be a new surrogate marker of multiple pathophysiologic processes in ADHF.
Study Limitations
First, we did not measure NT-proBNP levels at discharge/1 month after discharge and could not compare the prognostic power of RDW change with that of NT-proBNP change due to limitations of the retrospective study design. Further prospective studies are needed to show whether serial measurements of RDW have increased prognostic value compared to well-known markers such as NT-proBNP and ST2. 18,21 Second, we did not analyze the data for in-hospital mortality and CV events within 1 month, indicating that the present study may not be free from selection bias, although it was inevitable according to study design. Third, we could not demonstrate prognostic power of baseline LVEF and NT-proBNP level in the present analysis, despite the general concepts in HF. This might be due to the relatively skewed data measured in acute decompensated status. Fourth, we could not investigate hematologic laboratory parameters (eg, total iron binding capacity, serum ferritin level), which could help to distinguish the origin of increased RDW, even though we excluded the patients with transfusion or iron replacement therapy. 31 Finally, the present OH J et al. study group was characterized by a relatively low proportion of ischemic HF and β-blocker use, which may influence the present results. Therefore, a well-designed larger prospective study should be carried out in order to emphasize the clinical importance and application of repeated measurements of RDW after ADHF.
Conclusions
We have shown that repeated measurements of RDW increase the likelihood of predicting CV events compared to single measurements of RDW in ADHF patients. We found that positive RDW∆1Mdis-adm is a powerful independent prognostic factor for CV events. Therefore, repeated measurements of RDW is a simple and inexpensive method that may assist in determining CV risk in patients with ADHF.
